Search Menu

Home
HTB
2018
December
01

1 December 2018

Contents

Antiretrovirals

Doravirine (Pifeltro) and doravirine/TDF/3TC FDC (Delstrigo) approved in Europe

HTB RSS

Early access

HIV increases risk of severe COVID-19 in largest US study 3 August 2021
Evolution of neutralising antibody responses to natural infection and after vaccination 3 August 2021
Neutralising antibody levels from COVID vaccines correlate negatively with age 2 August 2021
HPV vaccine prevent penile infections in young gay men 1 August 2021
All early access reports

Current issues

August 2021
July 2021
June 2021
Back issues

Special report

HTB: no. 5 – plus HIV and COVID-19 (3 May 2021) 3 May 2021

More from HTB

Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage

Home

i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links: HIV positive; Advocate; Professional; Donate; Feedback

Advice and information: Q and A; Phoneline; Pocket info; Guides; HIV meds; Glossary

Research and conference reports: HTB; HTB South; Pipeline report

Publications and resources: Publications; Other resources; Translations; Slide sets; Order and subscribe

News and updates: News; Blogs

Advocates' network: UK-CAB; Training manual

i-Base: About us; Contact; Sitemap; Home

Find us on Facebook